IDH2 and central nervous system cancer: Since the initial discovery of mutations in the isocitrate dehydrogenase 1 (IDH1) gene by whole-genome sequencing in a large subset of human gliomas [1], and in acute myelogenous leukemia (AML) [2], much interest was focused on understanding consequences of mutations in IDH genes and their roles in tumor progression.